Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy - PubMed (original) (raw)
Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy
Saskia Schlossarek et al. Basic Res Cardiol. 2012 Jan.
Abstract
Several lines of evidence suggest that alterations of the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) may be involved in cardiac diseases. Little is known, however, in hypertrophic cardiomyopathy (HCM). This study studied these pathways in two mouse models of HCM that mainly differ by the presence or absence of truncated mutant proteins. Analyses were performed in homozygous Mybpc3-targeted knock-in (KI) mice, carrying a HCM mutation and exhibiting low levels of mutant cardiac myosin-binding protein C (cMyBP-C), and in Mybpc3-targeted knock-out (KO) mice expressing no cMyBP-C, thus serving as a model of pure cMyBP-C insufficiency. In the early postnatal development of cardiac hypertrophy, both models showed higher levels of ubiquitinated proteins and greater proteasomal activities. To specifically monitor the degradation capacity of the UPS with age, mice were crossed with transgenic mice that overexpress Ub(G76V)-GFP. Ub(G76V)-GFP protein levels were fourfold higher in 1-year-old KI, but not KO mice, suggesting a specific UPS impairment in mice expressing truncated cMyBP-C. Whereas protein levels of key ALP markers were higher, suggesting ALP activation in both mutant mice, their mRNA levels did not differ between the groups, underlying rather defective ALP-mediated degradation. Analysis of key proteins regulated in heart failure did not reveal specific alterations in KI and KO mice. Our data suggest (1) UPS activation in early postnatal development of cardiac hypertrophy, (2) specific UPS impairment in old KI mice carrying a HCM mutation, and (3) defective ALP as a common mechanism in genetically engineered mice with cardiac hypertrophy.
Similar articles
- Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.
Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T, Zolk O. Sarikas A, et al. Cardiovasc Res. 2005 Apr 1;66(1):33-44. doi: 10.1016/j.cardiores.2005.01.004. Cardiovasc Res. 2005. PMID: 15769446 - Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
Schlossarek S, Mearini G, Carrier L. Schlossarek S, et al. J Mol Cell Cardiol. 2011 Apr;50(4):613-20. doi: 10.1016/j.yjmcc.2011.01.014. Epub 2011 Feb 1. J Mol Cell Cardiol. 2011. PMID: 21291890 Review. - Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T. Stöhr A, et al. J Mol Cell Cardiol. 2013 Oct;63:189-98. doi: 10.1016/j.yjmcc.2013.07.011. Epub 2013 Jul 26. J Mol Cell Cardiol. 2013. PMID: 23896226 - Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy.
Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto Y, Shirayoshi Y, Kitakaze M, Carrier L, Hisatome I. Bahrudin U, et al. J Mol Biol. 2008 Dec 26;384(4):896-907. doi: 10.1016/j.jmb.2008.09.070. Epub 2008 Oct 7. J Mol Biol. 2008. PMID: 18929575 - Functional alterations of cardiac proteasomes under physiological and pathological conditions.
Tsukamoto O, Minamino T, Kitakaze M. Tsukamoto O, et al. Cardiovasc Res. 2010 Jan 15;85(2):339-46. doi: 10.1093/cvr/cvp282. Epub 2009 Aug 14. Cardiovasc Res. 2010. PMID: 19684034 Review.
Cited by
- Integrating Clinical Phenotype With Multiomics Analyses of Human Cardiac Tissue Unveils Divergent Metabolic Remodeling in Genotype-Positive and Genotype-Negative Patients With Hypertrophic Cardiomyopathy.
Nollet EE, Schuldt M, Sequeira V, Binek A, Pham TV, Schoonvelde SAC, Jansen M, Schomakers BV, van Weeghel M, Vaz FM, Houtkooper RH, Van Eyk JE, Jimenez CR, Michels M, Bedi KC Jr, Margulies KB, Dos Remedios CG, Kuster DWD, van der Velden J. Nollet EE, et al. Circ Genom Precis Med. 2024 Jun;17(3):e004369. doi: 10.1161/CIRCGEN.123.004369. Epub 2024 Jun 10. Circ Genom Precis Med. 2024. PMID: 38853772 Free PMC article. - Forward genetic screen using a gene-breaking trap approach identifies a novel role of _grin2bb_-associated RNA transcript (grin2bbART) in zebrafish heart function.
Angom RS, Joshi A, Patowary A, Sivadas A, Ramasamy S, K V S, Kaushik K, Sabharwal A, Lalwani MK, K S, Singh N, Scaria V, Sivasubbu S. Angom RS, et al. Front Cell Dev Biol. 2024 Mar 8;12:1339292. doi: 10.3389/fcell.2024.1339292. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38533084 Free PMC article. - Hypertrophic cardiomyopathy in MYBPC3 carriers in aging.
Ananthamohan K, Stelzer JE, Sadayappan S. Ananthamohan K, et al. J Cardiovasc Aging. 2024 Jan;4(1):9. doi: 10.20517/jca.2023.29. Epub 2024 Jan 11. J Cardiovasc Aging. 2024. PMID: 38406555 Free PMC article. - MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
Shridhar P, Glennon MS, Pal S, Waldron CJ, Chetkof EJ, Basak P, Clavere NG, Banerjee D, Gingras S, Becker JR. Shridhar P, et al. Circulation. 2023 Dec 5;148(23):1870-1886. doi: 10.1161/CIRCULATIONAHA.123.064332. Epub 2023 Oct 27. Circulation. 2023. PMID: 37886847 Free PMC article. - An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy.
Tudurachi BS, Zăvoi A, Leonte A, Țăpoi L, Ureche C, Bîrgoan SG, Chiuariu T, Anghel L, Radu R, Sascău RA, Stătescu C. Tudurachi BS, et al. Int J Mol Sci. 2023 Jun 22;24(13):10510. doi: 10.3390/ijms241310510. Int J Mol Sci. 2023. PMID: 37445689 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials